conference logo
Programme  Titles  Presenters  Topics 
Session 9 - Medulloblastoma II
Friday, May 8, 9:00am - 10:10am

MODERATORS: Michelle Monje-Deisseroth, Stefan Pfister


MB-14 Discovering the treatment refractory BTIC population in group 3 medulloblastoma
David Bakhshinyan*, Thusyanth Vijayakumar, Neha Garg, Branavan Manoranjan, Nicole McFarlane, Chitra Venugopal, Sheila Singh
McMaster University, Canada
MB-35 Very encouraging long-term survival and neurocognitive outcome of young children treated for medulloblastoma with sequential high dose chemotherapy
Lucie Lafay-Cousin6, Susan Chi2, Amy Smith3, Elizabeth Wells7, Jennifer Madden5, Ashley Margol4, Vijay Ramaswamy1, Emily Owen3, Douglas Strother1, Girish Dhall4, Nicholas Foreman5, Roger Packer7, Eric Bouffet*1
1The Hospital for Sick Children, Canada, 2Dana-Farber Cancer Institute, USA, 3Arnold Palmer Hospital for Children, USA, 4Children's Hospital of Los Angeles, USA, 5Children's Hospital of Colorado, USA, 6Alberta Children's Hospital, Canada, 7Children's National Medical Center, USA
PM-16 An animal model of 17p deletion in medulloblastoma
John Peacock*1,3, Anindya Bagchi4, Sean Egan3, Michael Taylor2,3
1The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Laboratory Medicine and Pathobiology, University of Toronto, Canada, 2Division of Neurosurgery, The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children,, Canada, 3Developmental & Stem Cell Biology, The Hospital for Sick Children, Canada, 4University of Minnesota, USA
PM-01 Neural derivatives from human embryonic stem cells: a cellular system to study the role of Otx2 in medulloblastoma progression.
Ravinder Kaur*1, Christopher Aiken1, Ludivine Coudiere Morrison1, Radhika Rao2, Marc Del Bigio3, Shravanti Rampalli2, Tamra Werbowetski-Ogilvie1
1Regenerative Medicine Program, Department of Biochemistry and Medical Genetics and Physiology, University of Manitoba, Canada, 2Centre for Inflammation and Tissue Homeostasis, Institute of Stem Cell Biology and Regenerative Medicine, NCBS-TIFR Campus, India, 3Department of Pathology, University of Manitoba, Canada
MB-27 Pathway analysis of a human neural stem cell model of aggressive medulloblastoma reveals CDK inhibition as a potential therapeutic modality
Allison Hanaford*1, Tenley Archer2, Pablo Tamayo3, Scott Pomeroy2,3, Charles Eberhart1, Eric Raabe1,4
1Johns Hopkins School of Medicine, USA, 2Boston Children's Hospital, USA, 3Eli and Edythe Broad Institute of MIT and Harvard University, USA, 4Johns Hopkins Hospital, USA
SG-04 The eEF2 kinase, a mediator of medulloblastoma adaptation to metabolic stress, supports fatty acid oxidation
Gabriel Leprivier*1, Raffaele Teperino2, Anders Kristensen1, Marc Remke3, Stefan Pfister4, Michael D. Taylor5, J. Andrew Pospisilik2, Poul H. Sorensen1
1British Columbia Cancer Research Centre and University of British Columbia, Canada, 2Max Planck Institute, Germany, 3University Hospital Düsseldorf, Germany, 4German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Germany, 5The Arthur and Sonia Labatt Brain Tumor Research Centre and University of Toronto, Canada
PM-06 Differential splicing of pyruvate kinase regulates progenitor cell cycle and medulloblastoma tumorigenesis
Katherine Tech*, Tia Fish, Andrew Crowther, Andrey Tikunov, Jeffrey Macdonald, Timothy Gershon
University of North Carolina at Chapel Hill, USA